These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 30071874)

  • 1. Plasma copeptin, kidney disease, and risk for cardiovascular morbidity and mortality in two cohorts of type 2 diabetes.
    Velho G; Ragot S; El Boustany R; Saulnier PJ; Fraty M; Mohammedi K; Fumeron F; Potier L; Marre M; Hadjadj S; Roussel R
    Cardiovasc Diabetol; 2018 Aug; 17(1):110. PubMed ID: 30071874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma Copeptin, Kidney Outcomes, Ischemic Heart Disease, and All-Cause Mortality in People With Long-standing Type 1 Diabetes.
    Velho G; El Boustany R; Lefèvre G; Mohammedi K; Fumeron F; Potier L; Bankir L; Bouby N; Hadjadj S; Marre M; Roussel R
    Diabetes Care; 2016 Dec; 39(12):2288-2295. PubMed ID: 27729425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma copeptin and renal outcomes in patients with type 2 diabetes and albuminuria.
    Velho G; Bouby N; Hadjadj S; Matallah N; Mohammedi K; Fumeron F; Potier L; Bellili-Munoz N; Taveau C; Alhenc-Gelas F; Bankir L; Marre M; Roussel R
    Diabetes Care; 2013 Nov; 36(11):3639-45. PubMed ID: 23863910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of soluble tumor necrosis factor receptors 1 and 2 with nephropathy, cardiovascular events, and total mortality in type 2 diabetes.
    Carlsson AC; Östgren CJ; Nystrom FH; Länne T; Jennersjö P; Larsson A; Ärnlöv J
    Cardiovasc Diabetol; 2016 Feb; 15():40. PubMed ID: 26928194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Copeptin predicts coronary artery disease cardiovascular and total mortality.
    Tasevska I; Enhörning S; Persson M; Nilsson PM; Melander O
    Heart; 2016 Jan; 102(2):127-32. PubMed ID: 26661323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma proprotein-convertase-subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes.
    El Khoury P; Roussel R; Fumeron F; Abou-Khalil Y; Velho G; Mohammedi K; Jacob MP; Steg PG; Potier L; Ghaleb Y; Elbitar S; Ragot S; Andreata F; Caligiuri G; Hadjadj S; Boileau C; Marre M; Abifadel M; Varret M; Hansel B
    Diabetes Obes Metab; 2018 Apr; 20(4):943-953. PubMed ID: 29205760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epicardial, pericardial and total cardiac fat and cardiovascular disease in type 2 diabetic patients with elevated urinary albumin excretion rate.
    Christensen RH; von Scholten BJ; Hansen CS; Heywood SE; Rosenmeier JB; Andersen UB; Hovind P; Reinhard H; Parving HH; Pedersen BK; Jørgensen ME; Jacobsen PK; Rossing P
    Eur J Prev Cardiol; 2017 Sep; 24(14):1517-1524. PubMed ID: 28650207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is the association of serum sodium with mortality in patients with type 2 diabetes explained by copeptin or NT-proBNP? (ZODIAC-46).
    Riphagen IJ; Logtenberg SJ; Groenier KH; van Hateren KJ; Landman GW; Struck J; Navis G; Kootstra-Ros JE; Kema IP; Bilo HJ; Kleefstra N; Bakker SJ
    Atherosclerosis; 2015 Sep; 242(1):179-85. PubMed ID: 26201002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Copeptin in patients with acute myocardial infarction and newly detected glucose abnormalities - A marker of increased stress susceptibility? A report from the Glucose in Acute Myocardial Infarction cohort.
    Smaradottir MI; Ritsinger V; Gyberg V; Norhammar A; Näsman P; Mellbin LG
    Diab Vasc Dis Res; 2017 Mar; 14(2):69-76. PubMed ID: 28118730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sex differences in the association between plasma copeptin and incident type 2 diabetes: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study.
    Abbasi A; Corpeleijn E; Meijer E; Postmus D; Gansevoort RT; Gans RO; Struck J; Hillege HL; Stolk RP; Navis G; Bakker SJ
    Diabetologia; 2012 Jul; 55(7):1963-70. PubMed ID: 22526609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Copeptin, a surrogate marker for arginine vasopressin, is associated with disease severity and progression in IgA nephropathy patients.
    Zittema D; van den Brand JA; Bakker SJ; Wetzels JF; Gansevoort RT
    Nephrol Dial Transplant; 2017 Jan; 32(suppl_1):i146-i153. PubMed ID: 28057871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between copeptin and declining glomerular filtration rate in people with newly diagnosed diabetes. The Skaraborg Diabetes Register.
    Pikkemaat M; Melander O; Bengtsson Boström K
    J Diabetes Complications; 2015; 29(8):1062-5. PubMed ID: 26321369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Copeptin, a surrogate marker for arginine vasopressin, is associated with cardiovascular and all-cause mortality in patients with type 2 diabetes (ZODIAC-31).
    Riphagen IJ; Boertien WE; Alkhalaf A; Kleefstra N; Gansevoort RT; Groenier KH; van Hateren KJ; Struck J; Navis G; Bilo HJ; Bakker SJ
    Diabetes Care; 2013 Oct; 36(10):3201-7. PubMed ID: 23757433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary Potassium Excretion and Renal and Cardiovascular Complications in Patients with Type 2 Diabetes and Normal Renal Function.
    Araki S; Haneda M; Koya D; Kondo K; Tanaka S; Arima H; Kume S; Nakazawa J; Chin-Kanasaki M; Ugi S; Kawai H; Araki H; Uzu T; Maegawa H
    Clin J Am Soc Nephrol; 2015 Dec; 10(12):2152-8. PubMed ID: 26563378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Copeptin, a surrogate marker for arginine vasopressin, is associated with declining glomerular filtration in patients with diabetes mellitus (ZODIAC-33).
    Boertien WE; Riphagen IJ; Drion I; Alkhalaf A; Bakker SJ; Groenier KH; Struck J; de Jong PE; Bilo HJ; Kleefstra N; Gansevoort RT
    Diabetologia; 2013 Aug; 56(8):1680-8. PubMed ID: 23624546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Copeptin and the risk of incident stroke, CHD and cardiovascular mortality in older men with and without diabetes: The British Regional Heart Study.
    Wannamethee SG; Welsh P; Lennon L; Papacosta O; Whincup PH; Sattar N
    Diabetologia; 2016 Sep; 59(9):1904-12. PubMed ID: 27312697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma Copeptin, AVP Gene Variants, and Incidence of Type 2 Diabetes in a Cohort From the Community.
    Roussel R; El Boustany R; Bouby N; Potier L; Fumeron F; Mohammedi K; Balkau B; Tichet J; Bankir L; Marre M; Velho G
    J Clin Endocrinol Metab; 2016 Jun; 101(6):2432-9. PubMed ID: 27049477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of serum concentration of TNFR1 with all-cause mortality in patients with type 2 diabetes and chronic kidney disease: follow-up of the SURDIAGENE Cohort.
    Saulnier PJ; Gand E; Ragot S; Ducrocq G; Halimi JM; Hulin-Delmotte C; Llaty P; Montaigne D; Rigalleau V; Roussel R; Velho G; Sosner P; Zaoui P; Hadjadj S;
    Diabetes Care; 2014 May; 37(5):1425-31. PubMed ID: 24623026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Copeptin and insulin-like growth factor binding protein-1 during follow-up after an acute myocardial infarction in patients with type 2 diabetes: A report from the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction 2 cohort.
    Smáradóttir MI; Catrina SB; Brismar K; Norhammar A; Gyberg V; Mellbin LG
    Diab Vasc Dis Res; 2019 Jan; 16(1):22-27. PubMed ID: 30309264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma Copeptin and Decline in Renal Function in a Cohort from the Community: The Prospective D.E.S.I.R. Study.
    Roussel R; Matallah N; Bouby N; El Boustany R; Potier L; Fumeron F; Mohammedi K; Balkau B; Marre M; Bankir L; Velho G
    Am J Nephrol; 2015; 42(2):107-14. PubMed ID: 26346607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.